pg. 1
N5431 FNP 2 FEMALE GU/REPRODUCTIVE EXAM
NEWEST 2025 ACTUAL EXAM| COMPLETE
QUESTIONS WITH CORRECT DETAILED ANSWERS
(VERIFIED ANSWERS ) ALREADY GRADED A+| N5431
FNP 2 FEMALE GU/REPRODUCTIVE ( NEWEST!!)
The typical HT regimen contains how much of the estrogen dose of COC? - ANSWER - one-fourth
When reviewing the use of nutritional supplements for the management
of menopausal symptoms, the NP considers that: - ANSWER - few high-
quality studies support the use of these products
Many over-the-counter progesterone creams contain sterols that the human body is unable to use, true or false? - ANSWER - True
In advising a woman about menopause, the NP considers that - ANSWER - hot flashes and night sweats occur in about 80% of women
Findings in estrogen deficiency (atrophic) vaginitis include: - ANSWER
- a pH greater than 5.0
A 53-year-old woman who is taking hormone therapy (HT) with conjugated equine estrogen, 0.625 mg/d with MPA, 2.5 mg, has
bothersome atrophic vaginitis symptoms. You advise that: - ANSWER -
topical estrogen may be helpful 1 / 3
pg. 2 For a woman with bothersome hot flashes who cannot take HT, alternative options with demonstrated efficacy include the use of all of
the following except: - ANSWER - clonidine (helpful- gabapentin,
sertraline, venlafaxine)
Absolute contraindication to postmenopausal HT includes: - ANSWER -
unexplained vaginal bleeding
In advising a perimenopausal woman about HT, you consider that it
may: - ANSWER - help preserve bone density
Postmenopausal HT use can result in: - ANSWER - a reduction in the
frequency and severity of vasomotor symptoms
The progestin component of HT is given to: - ANSWER - minimize
endometrial hyperplasia
Concerning selective estrogen receptor modulator therapy such as
raloxifene (Evista): - ANSWER - Osteoporosis risk is reduced with use
During perimenopause, what is likely to be noted? - ANSWER - symptoms are most likely in the week before the onset of the menses
What is likely to be noted with short term (less than 1 to 2 years) HT use in a post-menopausal woman? - ANSWER - minimized menopausal symptoms 2 / 3
pg. 3 Which body area has the greatest concentration of estrogen receptors? - ANSWER – vulva
What is most commonly found after 1 year of Depo-Provera use? - ANSWER - Weight gain
What advice would the provider give to a patient newly prescribed COC containing progestin drospirenone (Yasmin, Yaz)? - ANSWER - Avoid using potassium-containing salt substitutes
With genitourinary tract exposure to the spermicide nonoxynol-9, a
woman is likely at increased risk for: - ANSWER - urinary tract
infection
With the use of levonorgestrel intrauterine system (Mirena), what is normally noted? - ANSWER - Reduction in menstrual flow
The reductions in free androgens noted in a woman using COC can yield
an improvement in: - ANSWER - acne vulgaris
The recommended length of use of Depo-Provera is: - ANSWER - no
more than 2 years
When can a woman safely conceive after discontinuing COC? - ANSWER - immediately
- / 3